|
CA3049980A1
(en)
|
2017-01-23 |
2018-07-26 |
Regeneron Pharmaceuticals, Inc. |
Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
|
|
CA3059348A1
(en)
|
2017-04-11 |
2018-10-18 |
Regeneron Pharmaceuticals, Inc. |
Assays for screening activity of modulators of members of the hydroxysteroid (17-beta) dehydrogenase (hsd17b) family
|
|
EP3652312A1
(en)
|
2017-07-14 |
2020-05-20 |
Editas Medicine, Inc. |
Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
|
|
KR102712142B1
(ko)
|
2017-07-31 |
2024-10-07 |
리제너론 파마슈티칼스 인코포레이티드 |
Cas-형질전환 마우스 배아 줄기 세포 및 마우스 및 이것의 용도
|
|
CN111182790A
(zh)
|
2017-07-31 |
2020-05-19 |
瑞泽恩制药公司 |
Crispr报告体非人类动物及其用途
|
|
WO2019067875A1
(en)
|
2017-09-29 |
2019-04-04 |
Regeneron Pharmaceuticals, Inc. |
NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE
|
|
AU2018348195B2
(en)
|
2017-10-11 |
2025-05-15 |
Regeneron Pharmaceuticals, Inc. |
Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
|
|
EP3592140A1
(en)
|
2018-03-19 |
2020-01-15 |
Regeneron Pharmaceuticals, Inc. |
Transcription modulation in animals using crispr/cas systems
|
|
MY207352A
(en)
|
2018-03-21 |
2025-02-21 |
Regeneron Pharma |
17-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|
|
AU2019291918B2
(en)
|
2018-06-29 |
2025-06-12 |
Editas Medicine, Inc. |
Synthetic guide molecules, compositions and methods relating thereto
|
|
JP7578590B2
(ja)
|
2018-10-18 |
2024-11-06 |
インテリア セラピューティクス，インコーポレーテッド |
第ｉｘ因子を発現するための組成物及び方法
|
|
KR20220004648A
(ko)
*
|
2019-03-28 |
2022-01-11 |
인텔리아 테라퓨틱스, 인크. |
Ttr 가이드 rna, 및 rna-가이드 dna 결합제를 암호화하는 폴리뉴클레오티드를 포함하는 조성물 및 방법
|
|
WO2020247452A1
(en)
|
2019-06-04 |
2020-12-10 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
|
|
CN113939595A
(zh)
|
2019-06-07 |
2022-01-14 |
瑞泽恩制药公司 |
包括人源化白蛋白基因座的非人动物
|
|
KR20220024053A
(ko)
|
2019-06-14 |
2022-03-03 |
리제너론 파마슈티칼스 인코포레이티드 |
타우병증의 모델
|
|
WO2021026318A2
(en)
*
|
2019-08-06 |
2021-02-11 |
The Penn State Research Foundation |
Engineered crispr/cas9 systems for simultaneous long-term regulation of multiple targets
|
|
US12521451B2
(en)
|
2019-11-08 |
2026-01-13 |
Regeneron Pharmaceuticals, Inc. |
CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy
|
|
WO2021119006A1
(en)
*
|
2019-12-09 |
2021-06-17 |
Caribou Biosciences, Inc. |
Crispr abasic restricted nucleotides and crispr accuracy via analogs
|
|
AU2020401206A1
(en)
*
|
2019-12-11 |
2022-07-14 |
Intellia Therapeutics, Inc. |
Modified guide RNAs for gene editing
|
|
CN115362256A
(zh)
|
2020-02-07 |
2022-11-18 |
因特利亚治疗公司 |
用于激肽释放酶（klkb1）基因编辑的组合物和方法
|
|
US12115230B2
(en)
*
|
2020-04-09 |
2024-10-15 |
Verve Therapeutics, Inc. |
Base editing of ANGPTL3 and methods of using same for treatment of disease
|
|
US20210388348A1
(en)
*
|
2020-05-12 |
2021-12-16 |
University Of Massachusetts |
Modified guide rnas for crispr genome editing
|
|
EP4259792A1
(en)
|
2020-12-11 |
2023-10-18 |
Intellia Therapeutics, Inc. |
Polynucleotides, compositions, and methods for genome editing involving deamination
|
|
MX2023006878A
(es)
|
2020-12-11 |
2023-07-31 |
Intellia Therapeutics Inc |
Composiciones y métodos para reducir el mhc de clase ii en una célula.
|
|
EP4267723A1
(en)
|
2020-12-23 |
2023-11-01 |
Intellia Therapeutics, Inc. |
Compositions and methods for genetically modifying ciita in a cell
|
|
WO2022140586A2
(en)
|
2020-12-23 |
2022-06-30 |
Intellia Therapeutics, Inc. |
Compositions and methods for reducing hla-a in a cell
|
|
WO2022170193A2
(en)
|
2021-02-08 |
2022-08-11 |
Intellia Therapeutics, Inc. |
T-cell immunoglobulin and mucin domain 3 (tim3) compositions and methods for immunotherapy
|
|
EP4288088A2
(en)
|
2021-02-08 |
2023-12-13 |
Intellia Therapeutics, Inc. |
Lymphocyte activation gene 3 (lag3) compositions and methods for immunotherapy
|
|
JP2024505672A
(ja)
|
2021-02-08 |
2024-02-07 |
インテリア セラピューティクス，インコーポレイテッド |
免疫療法のためのナチュラルキラー細胞受容体２ｂ４組成物及び方法
|
|
AU2022227650A1
(en)
*
|
2021-02-25 |
2023-10-12 |
Celyntra Therapeutics Sa |
Compositions and methods for targeting, editing, or modifying genes
|
|
JP2024534114A
(ja)
|
2021-08-24 |
2024-09-18 |
インテリア セラピューティクス，インコーポレイテッド |
細胞療法用のプログラム細胞死タンパク質１（ｐｄ１）組成物及び方法
|
|
GB2702733A
(en)
*
|
2021-09-22 |
2026-06-24 |
Verve Therapeutics Inc |
Gene editing of PCSK9 or ANGPTL3 and compositions and methods of using same for treatment of disease
|
|
WO2023081200A2
(en)
|
2021-11-03 |
2023-05-11 |
Intellia Therapeutics, Inc. |
Cd38 compositions and methods for immunotherapy
|
|
EP4426836A1
(en)
*
|
2021-11-03 |
2024-09-11 |
Intellia Therapeutics, Inc. |
Modified guide rnas for gene editing
|
|
AU2022408167A1
(en)
|
2021-12-08 |
2024-06-06 |
Regeneron Pharmaceuticals, Inc. |
Mutant myocilin disease model and uses thereof
|
|
CN118974256A
(zh)
*
|
2022-03-29 |
2024-11-15 |
锐正基因(苏州)有限公司 |
用于治疗转甲状腺素蛋白淀粉样变性的组合物和方法
|
|
CN114574598B
(zh)
*
|
2022-04-02 |
2023-08-08 |
中国农业科学院北京畜牧兽医研究所 |
鉴定或辅助鉴定猪5/6肋眼肌面积的方法
|
|
KR20250037788A
(ko)
*
|
2022-06-15 |
2025-03-18 |
빔 테라퓨틱스, 인크. |
보체 활성화를 감소시키기 위한 조성물 및 방법
|
|
CN119384498A
(zh)
|
2022-06-16 |
2025-01-28 |
因特利亚治疗公司 |
用于对细胞进行遗传修饰的方法和组合物
|
|
EP4540389A2
(en)
|
2022-06-16 |
2025-04-23 |
Intellia Therapeutics, Inc. |
Compositions and methods for reducing mhc class i in a cell
|
|
WO2024006955A1
(en)
|
2022-06-29 |
2024-01-04 |
Intellia Therapeutics, Inc. |
Engineered t cells
|
|
WO2024003810A1
(en)
*
|
2022-06-30 |
2024-01-04 |
Geneditbio Limited |
Guide rna with chemical modifications
|
|
JP2026506287A
(ja)
|
2022-12-21 |
2026-02-24 |
インテリア セラピューティクス，インコーポレイテッド |
プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）編集のための組成物及び方法
|
|
CN120418427A
(zh)
|
2022-12-23 |
2025-08-01 |
因特利亚治疗公司 |
用于基因组编辑的系统和方法
|
|
WO2024186890A1
(en)
|
2023-03-06 |
2024-09-12 |
Intellia Therapeutics, Inc. |
Compositions and methods for hepatitis b virus (hbv) genome editing
|
|
TW202503051A
(zh)
|
2023-03-07 |
2025-01-16 |
美商英特利亞醫療公司 |
用於免疫療法之ｃｉｓｈ組合物及方法
|
|
JP2026523341A
(ja)
|
2023-05-15 |
2026-07-14 |
エヌクロマ・バイオ，インコーポレーテッド |
Ｈｂｖ遺伝子発現のエピジェネティック調節のための組成物および方法
|
|
WO2025007951A1
(zh)
*
|
2023-07-06 |
2025-01-09 |
上海交通大学 |
一种靶向ttr的sacas9 sgrna及其修饰方式
|
|
WO2025038646A1
(en)
|
2023-08-14 |
2025-02-20 |
Intellia Therapeutics, Inc. |
Cd70 car-t compositions and methods for cell-based therapy
|
|
WO2025038637A1
(en)
|
2023-08-14 |
2025-02-20 |
Intellia Therapeutics, Inc. |
Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2)
|
|
TW202515994A
(zh)
|
2023-08-14 |
2025-04-16 |
美商英特利亞醫療公司 |
用於對ｃｄ７０進行基因修飾之組合物及方法
|
|
EP4777114A1
(en)
*
|
2023-09-14 |
2026-07-22 |
Empirico Inc. |
Modified oligonucleotides
|
|
AU2024374554A1
(en)
|
2023-11-10 |
2026-05-21 |
Intellia Therapeutics, Inc. |
Compositions, methods, and systems for genomic editing
|
|
WO2025128871A2
(en)
|
2023-12-13 |
2025-06-19 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025137301A1
(en)
|
2023-12-20 |
2025-06-26 |
Intellia Therapeutics, Inc. |
Methods for rapid engineering of cells
|
|
IL330230A
(en)
|
2023-12-20 |
2026-08-01 |
Intellia Therapeutics Inc |
Engineered T cells
|
|
WO2025184520A1
(en)
|
2024-02-29 |
2025-09-04 |
Intellia Therapeutics, Inc. |
Compositions and methods for angiopoietin like 3 (angptl3) editing
|
|
CN117925623B
(zh)
*
|
2024-03-20 |
2024-06-07 |
北京引正基因科技有限公司 |
用于hao1基因编辑和治疗ph1的组合物
|
|
WO2025240946A1
(en)
|
2024-05-17 |
2025-11-20 |
Intellia Therapeutics, Inc. |
Lipid nanoparticles and lipid nanoparticle compositions
|
|
WO2025255308A1
(en)
|
2024-06-07 |
2025-12-11 |
Intellia Therapeutics, Inc. |
Cd8 co-receptor chimeric polypeptides in tcr cell therapy
|
|
TW202617987A
(zh)
*
|
2024-06-26 |
2026-05-01 |
美商英特利亞醫療公司 |
用於基因體編輯之經修飾之嚮導ｒｎａ
|
|
WO2026097018A1
(en)
|
2024-11-04 |
2026-05-07 |
Intellia Therapeutics, Inc. |
Polypeptides, polynucleotides, compositions, and methods for genome editing involving chromatin remodelers
|
|
WO2026163162A1
(en)
|
2025-01-31 |
2026-08-06 |
Intellia Therapeutics, Inc. |
Enhanced cas9 variants and uses thereof
|